PhRMA submits comments to CMS on Medicaid proposed rule

In response to the Centers for Medicare and Medicaid Services ’ (CMS) proposed rule regarding changes to Medicaid,PhRMA provided feedback on how the changes included would have widespread impacts on the biopharmaceutical marketplace and patient care. Specifically, PhRMA noted two significant areas of concern for the Administration to consider.

Source: The Catalyst - July 21, 2020 Category: Pharmaceuticals Tags: Patient Assistance Programs Medicaid Value-Based Contracting Source Type: news